BackKaleido Biosciences Overview

Kaleido Biosciences Operating Income

Track Kaleido Biosciences's operating income ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

N/A

As of Sep 30, 2023

Annual Operating Income (TTM)

N/A

Trailing 12 months ending Sep 30, 2023

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Kaleido Biosciences (KLDO) FAQ

As of the most recent data (September 2023), KLDO shows a operating income of $0. That compares with $-65M in the prior-year period — up 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, KLDO's operating income is now $0 (was $-65M) — a 100.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Kaleido Biosciences is outperforming or lagging.

Tracking KLDO's operating income over time shows whether Kaleido Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $-65M in the prior-year period — up 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Kaleido Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $0) with ownership activity and broader fundamentals.

Kaleido Biosciences's operating income is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.